Stock Groups

U.S. FDA cuts gap for Moderna COVID-19 booster dose to five months -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO A healthcare worker makes a syringe containing the Moderna COVID-19 vaccination at SOMOS Community care’s pop-up vaccine site during New York City’s COVID-19 pandemic. This was January 29, 2021. REUTERS/Mike

(Reuters) – The U.S. Food and Drug Administration announced Friday that it reduced the time between the primary and secondary series. Moderna (NASDAQ: COVID-19 vaccine, and booster dose of one month each for those aged 18 years or older to at most five months.

Peter Marks from the FDA’s Center for Biologics Evaluation and Research stated that vaccination is the best way to protect ourselves against COVID-19.

Following Monday’s agency decision to decrease the interval required for a booster of, the move was made. Pfizer BioNTech COVID-19 vaccine has been increased to six months (NYSE:). This is because it may offer better protection against Omicron variants that are rapidly spreading.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.

[ad_2]